A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CREDENCE
- Sponsors Janssen Research & Development
- 12 Jun 2017 Status changed from recruiting to active, no longer recruiting according to a Janssen media release.
- 08 May 2017 Planned End Date changed from 20 Jan 2020 to 28 Jun 2019.
- 06 Apr 2017 Planned primary completion date changed from 11 Feb 2019 to 28 Jun 2019.